Zentalis Pharmaceuticals (ZNTL) Total Current Liabilities (2019 - 2026)

Zentalis Pharmaceuticals has reported Total Current Liabilities for 8 years, with the latest figure at $35.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 28.72% year-over-year to $35.2 million; the trailing twelve-month figure through Mar 2026 stood at $35.2 million (down 28.72% YoY), and the FY2025 full-year result was $36.6 million, down 30.66% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $35.2 million, down from $36.6 million in the prior quarter.
• The five-year high for Total Current Liabilities was $69.4 million in Q4 2023, with the low at $35.2 million in Q1 2026.
• Average Total Current Liabilities over 5 years is $50.9 million, with a median of $52.7 million recorded in 2024.
• Year-over-year, Total Current Liabilities jumped 44.85% in 2022 and plunged 41.49% in 2025.
• Tracing ZNTL's Total Current Liabilities over 5 years: stood at $56.6 million in 2022, then advanced by 22.45% to $69.4 million in 2023, then retreated by 23.99% to $52.7 million in 2024, then plunged by 30.66% to $36.6 million in 2025, then dropped by 3.62% to $35.2 million in 2026.
• The last three Total Current Liabilities figures came in at $35.2 million (Q1 2026), $36.6 million (Q4 2025), and $37.2 million (Q3 2025), per Business Quant data.

Peer Comparison